Skip to content
Screener

TransMedics Group, Inc. TMDX Operating Cash Flow

Operating Cash Flow at other companies

CareDx logo
CareDxCDNA
$4.33M+116%
LivaNova logo
LivaNovaLIVN
$66.59M+5.8%
SRT
Strata Critical MedicalSRTA
$3.89M+1,679%
Insight Molecular Diagnostics Inc. logo
Insight Molecular Diagnostics Inc.IMDX
-$7.64M-30.8%
ICU Medical logo
ICU MedicalICUI
$80.15M+615%
Stereotaxis logo
StereotaxisSTXS
-$3.44M-93.5%

Other financials

Income statement

See full
Revenue$173.9M+21.2%
Gross profit$101.2M+14.7%
Operating income$13.3M-51.5%
Net income$7.3M-71.5%
EPS (diluted)$0.20-71.4%

Balance sheet

See full
Cash & equivalents$461.7M+48.9%
Total debt$409.9M+505%
Total equity$494.0M+85.5%
Total assets$1.4B+71.3%

Cash flow

See full
CapEx$36.7M+35.6%
Free cash flow-$12.1M+59.4%

Valuation

See full
Market cap$2.78B-31.3%
Enterprise value$2.73B-26.6%
P/E16.2×-40.3×
P/S4.4×-3.2×

Profitability

See full
Gross margin59.1%-0.4pp
Operating margin14.9%+4.1pp
Net margin27%+17.0pp
FCF margin23.8%

Returns & leverage

See full
Return on equity45.2%+22.2pp
Debt / equity0.8×+0.6×
Current ratio6.7×-2.4×

Where this comes from

Reported directly by TransMedics Group, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The source filing: TransMedics Group, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-206453
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Accrued expenses and other current liabilities(3,105)(4,644)
Deferred revenue40330
Operating lease liabilities(805)(664)
Net cash provided by (used in) operating activities24,533(2,855)
Cash flows from investing activities:
Purchases of property, plant and equipment(36,657)(27,038)
Net cash used in investing activities(36,657)(27,038)
Cash flows from financing activities:

Item 1. Financial Statements (Unaudited)

FAQ

What is TransMedics Group, Inc.'s operating cash flow?
TransMedics Group, Inc. (TMDX) reported operating cash flow of $24.53M in Q1 2026.
How has TransMedics Group, Inc.'s operating cash flow changed year-over-year?
TransMedics Group, Inc.'s operating cash flow increased by 959.3% year-over-year, from -$2.86M to $24.53M.
What is the long-term trend for TransMedics Group, Inc.'s operating cash flow?
Over 3 years (2021 to 2025), TransMedics Group, Inc.'s operating cash flow has grown at a 88.3% compound annual growth rate (CAGR), from -$28.86M to $192.84M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.

Ask your AI about TransMedics Group, Inc.'s operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude